- Home
- Applications
- immuno oncology
Refine by
Immuno Oncology Product Applications
7 applications found
We are currently focusing on 4 medical areas - infectious diseases, immuno-oncology, rare diseases and autoimmune ...
ByModerna, Inc. based in Cambridge, MASSACHUSETTS (USA)
AlNovo is pioneering new therapeutic modalities based on our Novobinder Platform to harness the power of the human immune system to directly attack cancer ...
ByAinovo Biotech Inc. based in Sacramento, CALIFORNIA (USA)
Laminar Wash technology is for scientists who believe that quantitative flow cytometry is critical to cell therapy, immuno-oncology, and other fields where cell analysis is important. ...
ByCuriox Biosystems Pte Ltd based in Singapore, SINGAPORE
Microbiotica has programs in IBD, Immuno-oncology and Gut Epithelial Barrier Repair developing medicines and biomarkers based on microbiota. ...
ByMicrobiotica Limited based in Little Chesterford, UNITED KINGDOM
Data from examining the immune repertoire of cancer patients can be used to identify patterns associated with positive outcomes and monitor the progress of immunotherapies in clinical trials. Single cell immune sequencing technologies provide an even more granular view of individual T cell or B cell populations following immunotherapy, providing unprecedented detail for informing cancer ...
ByiRepertoire, Inc. based in Huntsville, ALABAMA (USA)
Monoclonal antibodies (mAbs) are used to treat patients in a variety of conditions such as infectious disease, cancer, and autoimmunity. Discovery of therapeutic antibodies is a laborious process, that depends on high-throughput screening of antibody candidates to determine antigen specificity. Immune repertoire analysis provides accurate, sensitive, and rapid detection of antibody sequences in panning rounds or exposured animal models, accelerating the discovery of ...
ByEnpicom B.V. based in s-Hertogenbosch, NETHERLANDS
Natural killer (NK) cells have long been known to play a significant role in the body’s innate immune response. They were first described in the 1970s, but only in the last 15 years has significant progress been made in understanding the complexities and therapeutic potential these cells offer in helping fight cancer and other diseases. Today, we know that NK cells not only detect and identify malignant cancer cells, but they also induce cancer cell death and even help trigger a broader adaptive immune ...
ByKiadis Pharma NV based in Amsterdam, NETHERLANDS